|
|
Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
I believe the Trump administration is about to take a direct stake in a tiny $2 stock.
A stock that controls the largest mineral reserve in the country.
This single site has enough gold to establish a new Fort Knox.
Enough silver to build 57 billion AI chips.
Enough copper to rebuild the U.S. electric grid - 25 times over.
Quite simply...
I believe it's the ultimate "Make America Great Again" stock.
And right now...
You have a chance to learn how to stake your claim.
Before the U.S. government makes its next move.
The only catch is...
You need to act before June 30.
That's when a landmark policy decision could reprice this stock, overnight.
Causing shares to quickly surge from $2 per share - to $20 or more over the next year alone.
Don't delay.
Click here to get complete details on what I predict is "Trump's next big buy".
Regards,
Jim Rickards
P.S. The Trump administration has taken a direct stake in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth. Each time, shares sprinted higher. Click here to see why I believe this one is next.
|
Eli Lilly and the GLP-1 Value Chain
Let's start with a number that should stop you mid-scroll: $10.1 billion. That is what Lilly's tirzepatide franchise – Mounjaro for diabetes, Zepbound for obesity – generated in a single quarter. Q3 2025. One quarter. It also happens to be the quarter tirzepatide became the world's best-selling drug, overtaking Merck's Keytruda, which had held that title for years.
That is not a small reshuffling. That is a changing of the guard in global pharma.
What the Numbers Actually Say
Full-year 2025 revenue came in at $65.2 billion, a 44.7% increase over 2024. Mounjaro alone generated $23.0 billion in 2025 revenue. Zepbound added $13.5 billion. Those two products – both built on tirzepatide, Lilly's dual GIP/GLP-1 receptor agonist – accounted for the overwhelming majority of the company's growth engine.
Q3 2025 told the most dramatic story. Total revenue hit $17.6 billion, up 54% year over year, driven by a 62% increase in volume. Gross margin that quarter came in at 82.9%. That is not a pharma company grinding through commoditized products. That is a company whose manufacturing economics are improving as scale increases – favorable product mix doing most of the heavy lifting even as realized prices drifted lower.
Slight tangent, but it matters: the pricing pressure people keep worrying about has so far been absorbed entirely by volume. U.S. volume grew 60% in Q3 2025 even as prices declined by high single digits. The volume engine is winning that math, for now.
Where Lilly Makes Its Money
Tirzepatide works by activating two hormonal receptors simultaneously – GIP and GLP-1 – which together suppress appetite, improve insulin sensitivity, and drive meaningful weight reduction. It is a dual-agonist mechanism that Novo Nordisk's semaglutide (a single GLP-1 agonist) does not replicate. That mechanism distinction matters clinically and commercially.
Mounjaro targets type 2 diabetes. Zepbound targets obesity and overweight with related conditions. Same molecule, two massive addressable markets, sold under different labels. The international expansion has added a third dimension – Mounjaro launched in China, Brazil, and India during 2025, with international volume growth running at 46% in Q1 2025 alone.
|
|
Apple just told us where the next decade of tech is headed Apple's appointment of a hardware engineer to CEO signals that the next wave of innovation will be built around devices. Immersed is already ahead of that trend with software and hardware designed to improve productivity. More than 1.5M professionals already use Immersed, with many spending up to 60 hours per week on the platform. Shares now available at $0.79 through a Reg A+ offering. See Why 8,000+ Investors Bought In Disclosure: This is a paid advertisement for Immersed Regulation A+ offering. Please read the offering circular at invest.immersed.com |
The Manufacturing Bet Is Already Made
Here is where the investment story gets structural. Lilly has committed to major manufacturing facilities in Texas ($6.5B), Alabama ($6B), Virginia ($5B), the Netherlands ($3B), Puerto Rico ($1.2B), and India ($1B). Most recently, an additional $4.5 billion was announced for Indiana manufacturing, bringing the company's total U.S. manufacturing commitment to approximately $27 billion.
This is not a company hedging its bets. This is a company that believes the demand curve is durable and is building the infrastructure to prove it.
- Q1 2025 U.S. revenue: $8.49 billion, up 49% year over year
- Q1 2025 international revenue: $4.24 billion, up 38% year over year
- Q3 2025 tirzepatide franchise: $10.1 billion combined (Mounjaro + Zepbound)
- Mounjaro Q3 2025 alone: $6.5 billion, up 109% from Q3 2024
- Full-year 2025 revenue: $65.2 billion
- 2026 revenue guidance: $80 billion to $83 billion
- 2026 non-GAAP EPS guidance: $33.50 to $35.00
- Q1 2026 EPS: $8.55, beating estimates of $6.85 by nearly 25%
- Lilly holds roughly 6 out of every 10 prescriptions in the injectable obesity and diabetes drug class
The Next Catalyst Most Investors Are Underweighting
Orforglipron – now branded Foundayo – received FDA approval for adults with obesity or overweight in 2026. It is a once-daily oral small molecule GLP-1 receptor agonist, taken without food or water restrictions. No injection. No refrigeration. No cold chain logistics. Phase 3 data showed meaningful body weight reduction across all three doses compared to placebo, with a safety profile consistent with injectable GLP-1 medicines.
Lilly has already stated it is confident in its ability to launch Foundayo worldwide without supply constraints – a claim it cannot yet make about tirzepatide, which has required years of capital-intensive manufacturing buildout to meet demand. An oral product with no supply ceiling is a materially different commercial story.
|
|
He Called Nvidia Before It Soared 5,000% He recommended Tesla before 3,500%, and AMD before 8,500%. Luke Lango has a track record few analysts alive can match. Now he's making his biggest call yet - ahead of the OpenAI and Anthropic IPOs. Get the ticker here free. |
What Could Go Wrong
Pricing pressure is real and it is not going away. Realized prices declined by high single digits in Q3 2025 and are expected to remain under pressure as pharmacy benefit managers negotiate harder and payer mix shifts. CVS Caremark moved to make Novo Nordisk's Wegovy the preferred GLP-1 on its formulary in mid-2025. That did not stop Lilly from posting a record quarter, but it is a signal that formulary access battles are escalating.
The pipeline is long, the spending is high. R&D expense hit $3.47 billion in Q3 2025, up 27% year over year. Marketing and selling costs rose 29% in the same quarter. Lilly is spending aggressively to defend its position and expand into new indications – retatrutide is in Phase 3 for obesity and knee osteoarthritis, and the company is running a combination study of Taltz and Zepbound for psoriatic arthritis. These are smart bets, but they carry execution risk.
At roughly $1,123 per share and a market cap around $1.07 trillion, LLY is not a bargain in the traditional sense. Analysts are carrying a 12-month average price target near $1,215. The NTM P/E has contracted meaningfully from earlier highs, but the stock still demands a premium multiple for what is – by any honest read – premium execution.
The Cheap Investor Scorecard
- Revenue growth (2025): 44.7% – exceptional
- Gross margin (Q3 2025): 82.9% – best-in-class pharma
- Tirzepatide franchise (Q3 2025): $10.1B combined – world's top-selling drug
- 2026 revenue guidance: $80B to $83B – implies continued ~25% growth
- Manufacturing commitment: $27B+ in U.S. facilities – serious long-term infrastructure
- Foundayo (orforglipron): FDA-approved oral GLP-1 – supply-unconstrained launch
- Market share: nearly 6 in 10 injectable obesity/diabetes prescriptions in the U.S.
- International momentum: new markets in China, Brazil, India now contributing volume
- Pipeline depth: retatrutide, eloralintide, combination studies all advancing
- Key risk to watch: Foundayo weekly prescription run rate at the August 2026 earnings call
|
|
"This stock has a 93% history of soaring, every spring" One of the most popular stocks in America has a 100% history of rising on one particular date - every single spring. In fact, it's gone up beginning this ONE specific day - year after year - at a rate fast enough to double your money in 12 months. Click here to see the name of the stock, free of charge. |
The bottom line is straightforward, even if the stock price is not cheap: if tirzepatide volume continues to absorb price declines and Foundayo finds its prescription footing through Q3 2026, the guidance path to $80-plus billion in revenue is credible. If either of those conditions cracks – formulary access deteriorates faster than expected, or Foundayo disappoints in early uptake data – the multiple contraction story gets more interesting in a way you do not want.
This one is worth watching closely.
Tidak ada komentar:
Posting Komentar